Anti-prostglandin therapy in prevention of side-effects of intrauterine contraceptive devices.
The efficacy of an anti-prostaglandin, tolfenamic acid (T.A.), in the prevention of side-effects after insertion of a copper-T200 intrauterine contraceptive device (I.U.D.) was evaluated in a double-blind trial in 160 women. T.A. relieved pain and reduced bleeding after insertion and during three subsequent menstruations without serious side-effects. A scoring system for the assessment of I.U.D. side-effects showed that the acceptability of I.U.D. was significantly better in women treated with T.A. than in those given placebo.
D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007435:Intrauterine Devices, Copper / Q000009:adverse effects*; D008599:Menstruation Disturbances / Q000209:etiology / Q000517:prevention & control*; D010146:Pain / Q000209:etiology / Q000517:prevention & control*; D010919:Placebos; D011448:Prostaglandin Antagonists / Q000627:therapeutic use*; D014592:Uterine Hemorrhage / Q000209:etiology / Q000517:prevention & control*; D062367:ortho-Aminobenzoates / Q000627:therapeutic use*
D010919:Placebos; D011448:Prostaglandin Antagonists; D062367:ortho-Aminobenzoates; C009500:tolfenamic acid